Investors

Corporate Profile
We are a clinical-stage biopharmaceutical company developing innovative therapies for rare forms of cancer and orphan diseases.

Leveraging our proprietary ERYCAPS platform, which uses a novel technology to encapsulate therapeutic drug substances inside erythrocytes, or red blood cells, we have developed a pipeline of product candidates targeting markets with high unmet medical needs. Our initial focus is on the treatment of blood cancers, including acute lymphoblastic leukemia, or ALL, and acute myeloid leukemia, or AML, by depriving tumors of nutrients necessary for their survival, which is referred to as tumor starvation.
Stock Quote
ERYP.PA (Common Stock)
ExchangeParis (Euro)
Price€24.15
Change (%)0.00 (0.00%)
Volume0
Data as of 08/23/17 5:35 p.m. ET
Refresh quote
Recent NewsMore >>
DateTitle  
04-Aug-2017ERYTECH Pharma: Information Related to Total Number of Voting Rights and Shares Composing the Share Capital –July 31st, 2017
Article 223-16 of general regulation of French Autorité des Marchés Financiers LYON, France--(BUSINESS WIRE)--Aug. 4, 2017-- Regulatory News: ERYTECH Pharma (Paris:ERYP) (ADR:EYRYY): Listing market: Euronext Paris from Euronext Market segment : segment C ISIN Code : FR0011471135 website : www.erytech.com Date   ... 
 Printer Friendly Version
12-Jul-2017ERYTECH Announces Collaboration with Queen’s University to Advance its Product Candidate for Rare Metabolic Disorders
LYON, France--(BUSINESS WIRE)--Jul. 12, 2017-- Regulatory News: ERYTECH Pharma (Paris:ERYP) (ADR:EYRYY) (Euronext Paris - ERYP), a French clinical-stage biopharmaceutical company developing innovative therapies for rare forms of cancer and orphan diseases, today announced that it has entered into a research collaboration with Queen’s University in Canada to advance the preclinical development of ERYTECH’s eryminase program specifically for... 
 Printer Friendly Version
04-Jul-2017ERYTECH Pharma: Information Related to Total Number of Voting Rights and Shares Composing the Share Capital –May 31st, 2017
Article 223-16 of general regulation of French Autorité des Marchés Financiers LYON, France--(BUSINESS WIRE)--Jul. 4, 2017-- Regulatory News: ERYTECH Pharma (Paris:ERYP) (ADR:EYRYY): Listing market: Euronext Paris from Euronext Market segment : segment C ISIN Code : FR0011471135 website : www.erytech.com Date   ... 
 Printer Friendly Version
07-Jun-2017ERYTECH Pharma: Annual General Meeting of June 27, 2017
Availability of documents related to the annual general meeting LYON, France--(BUSINESS WIRE)--Jun. 7, 2017-- Regulatory News: ERYTECH Pharma (Paris:ERYP) (ADR:EYRYY), the French biopharmaceutical company developing ‘tumor starvation’ treatments for acute leukemia and other oncology indications with unmet medical needs, announced today the modalities for making available the documents for the Annual General Meeting of June 27, 2017. ... 
 Printer Friendly Version
Upcoming EventsMore >>
DateTitle
09/11/17
Second Quarter and Half-Year 2017 Financial Results and Business Update: Press Release: Monday, September 11, 2017 (after market)
09/12/17 3:00 p.m. CET
Second Quarter and Half-Year 2017 Financial Results and Business Update: Conference Call
11/13/17
Third Quarter 2017 Financial Results and Business Update: Press Release: Monday, November 13, 2017 (after market)
Receive E-mail Alerts
Sign up to receive e-mail alerts whenever Erytech Pharma SA posts new information to the site. Just enter your e-mail address and click Submit.
 
Data provided by Nasdaq. Minimum 15 minutes delayed. View Attributions and Sources